Skip to main content
David Kandzari, MD, Cardiology, Atlanta, GA

DavidEKandzariMD

Cardiology Atlanta, GA

Adult Congenital Heart Disease, Interventional Cardiology

Physician

Dr. Kandzari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kandzari's full profile

Already have an account?

  • Office

    95 Collier Rd NW
    Ste 2065
    Atlanta, GA 30309
    Phone+1 404-605-2800
    Fax+1 404-720-0911

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Cardiovascular Disease, 1998 - 2002
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1995 - 1998
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1995

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2008 - Present
  • GA State Medical License
    GA State Medical License 2010 - 2026
  • TX State Medical License
    TX State Medical License 2008 - 2011
  • NC State Medical License
    NC State Medical License 1999 - 2008
  • VA State Medical License
    VA State Medical License 2004 - 2006
  • American Board of Internal Medicine Cardiovascular Disease
  • American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • Atlanta Magazine: Top Doctors Castle Connolly, 2011-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Original Investigations Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents: BIOFLOW V 2-Year Results  
    David E Kandzari, Ron Waksman, Donald E Cutlip, Elie G Gharib, ScienceDirect
  • Original Investigation Left Main Revascularization with PCI or CABG in Patients with Chronic Kidney Disease: EXCEL Trial  
    John D Puskas, David E Kandzari, Gennaro Giustino, Roxana Mehran, Martin B Leon, Philippe Genereux, Michael 3rd Ragosta, Charles A Simonton, Irving L Kron, Gregg W Stone, ScienceDirect
  • Focus on Left Main Interventions Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site: Results f...  
    Gregg W Stone, David E Kandzari, Nicholas J Lembo, ScienceDirect
  • Join now to see all

Lectures

  • Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the ... 
    Society for Cardiovascular Angiography and Interventions, Phoenix, Arizona - 1/19/2013
  • The Target BP Program: Ongoing and Future Studies 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/27/2019
  • Choose Carefully: The Best New Generation DES are Associated With Meaningful Improvements In Performance and Outcomes! 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
  • Join now to see all

Authored Content

  • Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the Randomized BIOFLOW V TrialJune 2020
  • Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the Randomized BIOFLOW V TrialJune 2020
  • The Day After a Primary EndpointMarch 2018
  • New-Onset Atrial Fibrillation After PCI or CABG for Left Main DiseaseFebruary 2018
  • New-Onset Atrial Fibrillation After PCI or CABG for Left Main DiseaseFebruary 2018
  • New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease the EXCEL TrialFebruary 2018
  • New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease the EXCEL TrialFebruary 2018
  • Join now to see all

Press Mentions

  • SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two Years
    SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two YearsOctober 28th, 2024
  • Medtronic’s Symplicity Spyral RDN Evaluated at 2 Years in SPYRAL HTN-ON MED
    Medtronic’s Symplicity Spyral RDN Evaluated at 2 Years in SPYRAL HTN-ON MEDOctober 28th, 2024
  • Cover Story | Renal Denervation: Expanding Care for Treatment-Resistant Hypertension
    Cover Story | Renal Denervation: Expanding Care for Treatment-Resistant HypertensionAugust 30th, 2024
  • Join now to see all

Professional Memberships